First Trust Advisors LP Boosts Holdings in Boston Scientific Corporation $BSX

First Trust Advisors LP raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 40.7% in the first quarter, Holdings Channel reports. The institutional investor owned 184,386 shares of the medical equipment provider’s stock after acquiring an additional 53,332 shares during the period. First Trust Advisors LP’s holdings in Boston Scientific were worth $11,570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the fourth quarter worth about $26,000. Bangor Savings Bank increased its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific in the first quarter worth about $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. BTIG Research lowered their price objective on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer decreased their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday. TD Cowen lowered their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Finally, Barclays lowered their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported revenue of $5.442 billion, up 7.5% year over year, and adjusted earnings of $0.86 per share versus the $0.83 consensus estimate. Cardiovascular sales increased 8.3%, while international growth was particularly strong in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Cost savings and product development may support longer-term growth. Boston Scientific is pursuing a multiyear restructuring program targeting approximately $500 million in annual savings, received FDA clearance for its TruSelect 2.6 Microcatheter and invested $1.5 billion in MiRus, including an option to acquire its TAVR business. The company also completed a $2 billion accelerated share repurchase.
• Positive Sentiment: Analysts remain broadly bullish despite lower targets. TD Cowen, Truist and BTIG retained “buy” ratings, while UBS reaffirmed its “buy” rating. However, their price targets were reduced to reflect more cautious near-term assumptions. What Are Wall Street Analysts’ Target Price for Boston Scientific Stock?
• Neutral Sentiment: Boston Scientific is acquiring Penumbra. Penumbra reported second-quarter revenue of $390.0 million, up 14.9%, with gross margin improving to 67.9%. The company will not provide full-year guidance or hold a conference call because of the pending acquisition by Boston Scientific. The deal could expand BSX’s thrombectomy and embolization portfolio, but integration and transaction costs remain factors for investors. Penumbra, Inc. Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Lower guidance overshadowed the quarterly beat. Boston Scientific now expects full-year adjusted EPS of $3.28–$3.32, below the prior $3.34–$3.41 range and analyst expectations of roughly $3.36. Third-quarter EPS and revenue guidance also fell short of consensus.
• Negative Sentiment: WATCHMAN and electrophysiology headwinds are weighing on expectations. Softer WATCHMAN demand, competition and slower EP growth prompted management to temper its outlook. The company also faces a product recall and expects restructuring costs of approximately $700 million to $800 million through 2029. Boston Scientific trims annual profit forecast on softer Watchman device demand

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $45.92 on Friday. The company has a market cap of $68.25 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.89 and a beta of 0.58. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm’s fifty day moving average is $46.35 and its two-hundred day moving average is $62.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.31 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.